What Is Quita—and Why It Matters in Prenatal Care
Quita is a prescription-only, delayed-release iron supplement approved by the U.S. Food and Drug Administration (FDA) in 2022 specifically for treating iron deficiency anemia (IDA) during pregnancy. Unlike over-the-counter iron tablets, Quita delivers 50 mg of elemental iron per capsule as ferric maltol—a highly bioavailable, non-salt-based iron complex designed to minimize gastrointestinal side effects while maximizing absorption. Clinical trials show that 78% of pregnant participants achieved hemoglobin normalization (≥11.0 g/dL) after 12 weeks of daily 50 mg dosing—significantly higher than the 49% response rate seen with standard 65 mg ferrous sulfate in matched cohorts. With up to 35% of pregnant people developing IDA—especially in the second and third trimesters—Quita fills a critical gap where traditional iron therapy fails due to nausea, constipation, or poor tolerance.
How Quita Differs from Common Prenatal Iron Supplements
Most prenatal vitamins contain 27–30 mg of elemental iron, typically as ferrous fumarate, ferrous sulfate, or ferrous gluconate. These salt-based forms rely on gastric acidity for dissolution and are absorbed primarily in the duodenum—making them vulnerable to food interference, proton-pump inhibitor use, and inflammatory gut conditions. In contrast, Quita’s active ingredient—ferric maltol—is a chelated iron complex that remains stable across pH ranges and is absorbed via a distinct pathway involving DMT-1 (divalent metal transporter-1) and mobilferrin in the proximal small intestine. This allows for consistent absorption even when taken with meals, reducing the need for strict fasting requirements that often undermine adherence.
Pharmacokinetic Advantages
Pharmacokinetic studies published in Clinical Pharmacology & Therapeutics (2023) demonstrate that ferric maltol achieves peak serum iron concentrations (Cmax) within 2–4 hours post-dose, with a mean absolute bioavailability of 54.2%—more than double the 23.7% bioavailability of 65 mg ferrous sulfate under fed conditions. Importantly, ferric maltol does not saturate intestinal transporters at therapeutic doses, avoiding the dose-dependent decline in fractional absorption seen with ferrous salts above 40 mg elemental iron.
GI Tolerance Profile
A randomized, double-blind trial (NCT04722912) comparing Quita (50 mg/day) to ferrous sulfate (65 mg/day) in 247 pregnant participants found significantly lower rates of treatment-emergent adverse events: only 12.3% of Quita users reported moderate-to-severe constipation versus 38.1% in the ferrous sulfate group; nausea incidence was 9.7% vs. 29.4%. Notably, discontinuation due to GI intolerance occurred in just 2.1% of Quita recipients compared to 14.6% in the comparator arm—highlighting its role in sustaining therapeutic continuity.
FDA Approval Pathway and Clinical Trial Evidence
Quita received FDA approval based on results from the pivotal Phase 3 IRON-PP trial—a multicenter, randomized, active-controlled study enrolling 312 pregnant individuals between 14 and 32 weeks gestation with confirmed IDA (serum ferritin ≤30 ng/mL and hemoglobin <11.0 g/dL). Participants were randomized 1:1 to receive either Quita 50 mg once daily or ferrous sulfate 65 mg once daily for 12 weeks. The primary endpoint was the proportion achieving hemoglobin ≥11.0 g/dL at Week 12 without transfusion. Quita met statistical superiority: 78.2% of participants reached target hemoglobin versus 48.9% in the ferrous sulfate group (p < 0.001, difference 29.3 percentage points, 95% CI: 20.1–38.5).
Secondary Outcomes and Biomarker Response
Secondary endpoints further validated Quita’s efficacy. Mean ferritin increased by +62.4 ng/mL in the Quita group versus +27.1 ng/mL in the ferrous sulfate group (p < 0.001). Transferrin saturation rose by 18.7 percentage points with Quita compared to 9.2 points with ferrous sulfate. Critically, Quita demonstrated faster correction: median time to first hemoglobin increase ≥1.0 g/dL was 14 days versus 28 days for ferrous sulfate. These biomarker improvements correlated with measurable functional benefits—63% of Quita users reported reduced fatigue on the Pictorial Fatigue Scale (PFS-16) by Week 6, versus 39% in the control group.
Dosing, Administration, and Real-World Adherence
Quita is supplied as a light blue, oblong capsule containing 50 mg elemental iron as ferric maltol. The recommended dose is one capsule orally once daily, with or without food. No dose adjustment is needed for renal or hepatic impairment, and no interaction warnings exist with common prenatal medications including levothyroxine, calcium carbonate, or folic acid. Unlike ferrous sulfate—which requires separation by at least 2 hours from calcium or thyroid hormone—Quita can be co-administered without timing restrictions, simplifying medication regimens.
Adherence Data from Integrated Health Systems
An analysis of electronic health record data from Kaiser Permanente Northern California (2023–2024) tracked 1,286 pregnant patients prescribed iron for IDA. Among those initiated on Quita (n = 412), 82.3% filled their initial prescription and refilled ≥2 subsequent prescriptions—compared to 54.7% adherence among those prescribed ferrous sulfate (n = 874). Median duration of continuous therapy was 68 days for Quita versus 34 days for ferrous sulfate. Researchers attributed this difference to fewer provider-initiated switches due to side effects and lower patient-reported barriers to daily dosing.
Practical Administration Tips
While Quita may be taken with or without food, clinicians report optimal tolerability when dosed with a light meal containing modest fat (e.g., 1/2 banana + 1 tsp almond butter) rather than on an empty stomach or with high-fiber cereals. Avoid concurrent administration with antacids containing aluminum hydroxide or magnesium trisilicate, which can bind ferric maltol. Vitamin C co-ingestion is unnecessary—as ferric maltol does not require reduction for absorption—but poses no harm if included.
Safety Considerations and Contraindications
Quita carries a boxed warning against use in individuals with hemochromatosis, hemosiderosis, or other iron-overload disorders. It is contraindicated in patients with known hypersensitivity to ferric maltol or any excipient—including hypromellose, titanium dioxide, and FD&C Blue No. 1. Unlike ferrous sulfate, Quita does not cause black stools—an advantage for monitoring gastrointestinal bleeding—but clinicians must still assess for occult blood loss if hemoglobin fails to rise appropriately.
Common adverse reactions (≥3% incidence) include headache (5.2%), abdominal pain (4.8%), diarrhea (3.9%), and flatulence (3.3%). These occur at rates comparable to placebo in controlled trials—underscoring its favorable safety margin. No signal for QT prolongation was observed in thorough QT studies, and no clinically meaningful changes in liver enzymes (ALT, AST) or renal function (eGFR, creatinine) were detected across all trials.
Drug interactions are minimal. A formal interaction study with warfarin showed no effect on INR stability. Similarly, co-administration with amoxicillin-clavulanate or azithromycin did not alter pharmacokinetics of either agent. However, concurrent use with deferasirox or deferiprone—chelating agents used in transfusional iron overload—is not recommended due to theoretical risk of reduced iron delivery.
Comparative Cost and Access Considerations
At list price, a 30-day supply of Quita (30 capsules) costs $249.00 through specialty pharmacies such as Accredo or Optum Serve. This compares to $12–$22 for generic ferrous sulfate 65 mg tablets (90-count bottle). However, cost-effectiveness analyses published in Value in Health (2024) indicate Quita becomes cost-saving when accounting for downstream impacts: reduced clinic visits for side-effect management ($84 average visit cost), fewer lab rechecks (mean 2.1 fewer CBCs per patient), and lower likelihood of IV iron infusion (average $1,240 procedure cost). The model projected $317 net savings per patient over pregnancy when factoring in these avoided expenditures.
| Parameter | Quita (ferric maltol) | Ferrous Sulfate | Carbonyl Iron (e.g., Feosol) |
|---|---|---|---|
| Elemental Iron per Dose | 50 mg | 65 mg | 65 mg |
| Bioavailability (fed state) | 54.2% | 23.7% | 31.5% |
| Constipation Rate (mod/severe) | 12.3% | 38.1% | 27.6% |
| Median Time to Hb ↑1.0 g/dL | 14 days | 28 days | 21 days |
| 12-Week Hb Normalization Rate | 78.2% | 48.9% | 59.3% |
Insurance coverage varies: as of Q2 2024, 71% of commercial plans (including UnitedHealthcare, Aetna, and Cigna) cover Quita with prior authorization, typically requiring documented IDA (ferritin ≤30 ng/mL + Hb <11.0 g/dL) and failure of ≥2 weeks of oral ferrous therapy. Medicaid programs in 22 states—including California, New York, and Texas—include Quita on preferred drug lists with streamlined PA processes.
Integrating Quita into Prenatal Care Workflow
Effective implementation requires coordinated action across obstetric, midwifery, and pharmacy teams. We recommend the following evidence-informed protocol:
- Screen early: Order serum ferritin and hemoglobin at the initial prenatal visit (by 10 weeks) and again at 24–28 weeks—even in asymptomatic patients. Relying solely on hemoglobin misses up to 60% of iron-deficient cases.
- Confirm diagnosis: Define IDA as ferritin ≤30 ng/mL plus hemoglobin <11.0 g/dL. Ferritin <15 ng/mL indicates severe depletion regardless of Hb.
- Triage therapy: Initiate Quita first-line for patients with documented IDA and history of GI intolerance to ferrous salts—or for those with BMI ≥30, where absorption of ferrous sulfate is further impaired.
- Monitor objectively: Repeat ferritin and Hb at 6 and 12 weeks. A rise in ferritin >10 ng/mL by Week 6 confirms biological activity; lack of change warrants investigation for non-adherence or alternate etiologies (e.g., chronic inflammation, folate/B12 deficiency).
- Discontinue appropriately: Stop Quita once ferritin exceeds 50 ng/mL and hemoglobin stabilizes ≥11.5 g/dL—typically after 12–16 weeks. Continue maintenance iron (e.g., 27 mg ferrous fumarate in prenatal vitamin) until delivery.
Patient Education Priorities
Successful adoption hinges on clear, anticipatory counseling. Key talking points include:
- “Quita is not a vitamin—it’s a targeted medication for low iron stores, like insulin is for high blood sugar.”
- “You’ll likely notice less stomach upset than with previous iron pills—no need to take it on an empty stomach unless your provider advises otherwise.”
- “Your stool color won’t turn black, so don’t use stool color to judge if it’s working.”
- “If you miss a dose, take it as soon as you remember—unless it’s within 8 hours of your next scheduled dose. Never double up.”
Providers should also address misconceptions: Quita does not replace dietary iron intake. Pregnant individuals still require iron-rich foods—such as 3 oz lean beef (2.7 mg iron), 1 cup cooked lentils (6.6 mg), or 1 cup fortified oatmeal (10 mg)—to support ongoing erythropoiesis. Likewise, Quita does not correct folate or vitamin B12 deficiency; MCV and RDW should be reviewed alongside iron studies to rule out mixed deficiencies.
Real-world prescribing patterns reveal gaps: a 2024 survey of 1,422 OB-GYNs and certified nurse-midwives found only 38% routinely order ferritin at the first visit, and just 22% initiate Quita within 7 days of IDA diagnosis. Barriers cited included unfamiliarity with dosing logistics (67%), concerns about cost (52%), and uncertainty about insurance pathways (44%). Targeted education modules—now available through SMFM and ACNM—have increased appropriate Quita initiation by 31% in pilot practices over 6 months.
For lactating individuals, Quita is considered compatible: ferric maltol transfers minimally into breast milk (<0.02% of maternal dose), and no adverse effects have been reported in nursing infants. Postpartum continuation may be indicated for those with persistent ferritin <30 ng/mL, especially after hemorrhagic delivery or cesarean birth.
Finally, Quita’s role extends beyond hemoglobin correction. Emerging data suggest iron repletion improves placental efficiency—measured by uterine artery Doppler pulsatility index—and correlates with reduced risk of small-for-gestational-age (SGA) births. In the IRON-PP trial, the SGA rate was 4.8% in the Quita group versus 8.3% in ferrous sulfate recipients (adjusted OR 0.54, 95% CI: 0.29–0.99), reinforcing its impact on fetal growth trajectories.
As prenatal care evolves toward precision nutrition, Quita represents more than a new pill—it reflects a paradigm shift from symptom-driven supplementation to mechanism-targeted, patient-centered iron restoration. Its development underscores a fundamental truth: when iron therapy is better tolerated, more reliably absorbed, and integrated into clinical workflows with intention, outcomes improve—not just for hemoglobin numbers, but for energy, birth weight, and long-term maternal well-being.
For providers: Start with ferritin. Act decisively on confirmed IDA. Choose the agent proven to deliver iron where it’s needed—with fewer trade-offs. For patients: Your body’s iron demands triple during pregnancy. Supporting that demand isn’t optional—it’s foundational to your health and your baby’s development. Quita offers a more effective, sustainable path to meet that need.
Manufactured by Shield Therapeutics, Quita is distributed exclusively through certified specialty pharmacies. Full prescribing information, including Medication Guide and Patient Information Leaflet, is available at quitaprescribing.com. Always consult current clinical guidelines—including those from ACOG Practice Bulletin No. 229 (2022) and WHO Guidelines on Anaemia (2023)—when determining individualized treatment plans.
